303 related articles for article (PubMed ID: 24275667)
41. Catabolism of factor VIIa bound to tissue factor in fibroblasts in the presence and absence of tissue factor pathway inhibitor.
Iakhiaev A; Pendurthi UR; Voigt J; Ezban M; Vijaya Mohan Rao L
J Biol Chem; 1999 Dec; 274(52):36995-7003. PubMed ID: 10601255
[TBL] [Abstract][Full Text] [Related]
42. A molecular dynamics simulation study to understand the effect of cholesterol and tissue factor palmitoylation on tissue factor-factor VIIa-factor Xa ternary complex in different lipid environments.
Banerjee S; Sen P
J Thromb Haemost; 2023 Apr; 21(4):917-932. PubMed ID: 36696201
[TBL] [Abstract][Full Text] [Related]
43. New insights into the biology of tissue factor pathway inhibitor.
Maroney SA; Mast AE
J Thromb Haemost; 2015 Jun; 13 Suppl 1(0 1):S200-7. PubMed ID: 26149025
[TBL] [Abstract][Full Text] [Related]
44. The second Kunitz domain of human tissue factor pathway inhibitor: cloning, structure determination and interaction with factor Xa.
Burgering MJ; Orbons LP; van der Doelen A; Mulders J; Theunissen HJ; Grootenhuis PD; Bode W; Huber R; Stubbs MT
J Mol Biol; 1997 Jun; 269(3):395-407. PubMed ID: 9199408
[TBL] [Abstract][Full Text] [Related]
45. Activity of secreted Kunitz domain 1 variants of tissue factor pathway inhibitor.
Johnson K; Zaror I; Bauer D; Choi Y; Creasey A; Innis M
Thromb Haemost; 1998 Oct; 80(4):585-7. PubMed ID: 9798974
[TBL] [Abstract][Full Text] [Related]
46. Hemostatic properties of a TFPI antibody.
Petersen LC
Thromb Res; 2012 May; 129 Suppl 2():S44-5. PubMed ID: 22405586
[TBL] [Abstract][Full Text] [Related]
47. Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor.
Hackeng TM; Seré KM; Tans G; Rosing J
Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3106-11. PubMed ID: 16488980
[TBL] [Abstract][Full Text] [Related]
48. A novel exosite on coagulation factor VIIa and its molecular interactions with a new class of peptide inhibitors.
Roberge M; Santell L; Dennis MS; Eigenbrot C; Dwyer MA; Lazarus RA
Biochemistry; 2001 Aug; 40(32):9522-31. PubMed ID: 11583151
[TBL] [Abstract][Full Text] [Related]
49. Reversible regulation of tissue factor-induced coagulation by glycosyl phosphatidylinositol-anchored tissue factor pathway inhibitor.
Ott I; Miyagi Y; Miyazaki K; Heeb MJ; Mueller BM; Rao LV; Ruf W
Arterioscler Thromb Vasc Biol; 2000 Mar; 20(3):874-82. PubMed ID: 10712416
[TBL] [Abstract][Full Text] [Related]
50. Targeting TFPI for hemophilia treatment.
Peterson JA; Maroney SA; Mast AE
Thromb Res; 2016 May; 141 Suppl 2(Suppl 2):S28-30. PubMed ID: 27207418
[TBL] [Abstract][Full Text] [Related]
51. Activity and regulation of factor VIIa analogs with increased potency at the endothelial cell surface.
Ghosh S; Ezban M; Persson E; Pendurthi U; Hedner U; Rao LV
J Thromb Haemost; 2007 Feb; 5(2):336-46. PubMed ID: 17092304
[TBL] [Abstract][Full Text] [Related]
52. Structure and biology of tissue factor pathway inhibitor.
Bajaj MS; Birktoft JJ; Steer SA; Bajaj SP
Thromb Haemost; 2001 Oct; 86(4):959-72. PubMed ID: 11686353
[TBL] [Abstract][Full Text] [Related]
53. Reactive oxygen species induce a procoagulant state in endothelial cells by inhibiting tissue factor pathway inhibitor.
Cimmino G; Cirillo P; Ragni M; Conte S; Uccello G; Golino P
J Thromb Thrombolysis; 2015 Aug; 40(2):186-92. PubMed ID: 25712553
[TBL] [Abstract][Full Text] [Related]
54. Tissue factor pathway inhibitor gene disruption.
Broze GJ
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S89-92. PubMed ID: 9819035
[TBL] [Abstract][Full Text] [Related]
55. Involvement of the heparanase procoagulant domain in bleeding and wound healing.
Crispel Y; Ghanem S; Attias J; Kogan I; Brenner B; Nadir Y
J Thromb Haemost; 2017 Jul; 15(7):1463-1472. PubMed ID: 28439967
[TBL] [Abstract][Full Text] [Related]
56. Recent estimates of the structure of the factor VIIa (FVIIa)/tissue factor (TF) and factor Xa (FXa) ternary complex.
Lee CJ; Chandrasekaran V; Wu S; Duke RE; Pedersen LG
Thromb Res; 2010 Apr; 125 Suppl 1():S7-S10. PubMed ID: 20156644
[TBL] [Abstract][Full Text] [Related]
57. Vascular endothelial growth factor production by fibroblasts in response to factor VIIa binding to tissue factor involves thrombin and factor Xa.
Ollivier V; Chabbat J; Herbert JM; Hakim J; de Prost D
Arterioscler Thromb Vasc Biol; 2000 May; 20(5):1374-81. PubMed ID: 10807756
[TBL] [Abstract][Full Text] [Related]
58. Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa.
Wesselschmidt R; Likert K; Girard T; Wun TC; Broze GJ
Blood; 1992 Apr; 79(8):2004-10. PubMed ID: 1562726
[TBL] [Abstract][Full Text] [Related]
59. Structural and functional characterization of tissue factor pathway inhibitor following degradation by matrix metalloproteinase-8.
Cunningham AC; Hasty KA; Enghild JJ; Mast AE
Biochem J; 2002 Oct; 367(Pt 2):451-8. PubMed ID: 12117418
[TBL] [Abstract][Full Text] [Related]
60. Activated factor XI increases the procoagulant activity of the extrinsic pathway by inactivating tissue factor pathway inhibitor.
Puy C; Tucker EI; Matafonov A; Cheng Q; Zientek KD; Gailani D; Gruber A; McCarty OJ
Blood; 2015 Feb; 125(9):1488-96. PubMed ID: 25587039
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
